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AIM The aims of this study were: (1) to determine the incidence and nature of adverse effects
on oral motor function after first injections of botulinum neurotoxin A (BoNT-A) in
submandibular glands for excessive drooling in children with central nervous system
disorders; and (2) to identify independent predictors of these adverse effects.
METHOD A cohort study involved 209 children (123 males, 86 females, aged 4–27y, median
8y 4mo), who received submandibular BoNT-A injections for drooling. Adverse effects were
categorized into swallowing, eating, drinking, articulation, and other problems. Univariable
logistic regression was used to study differences in patients with and without adverse effects.
Possible predictors were identified using multivariable logistic regression.
RESULTS Transient adverse effects occurred in 33% of the 209 BoNT-A treatments. Almost
80% of these were mild, versus 8.7% severe. Approximately 54% of the adverse effects
spontaneously resolved within 4 weeks; 3% still existed after 32 weeks. A diagnosis of
cerebral palsy, higher range of BoNT-A dosage, and a pre-treatment drooling quotient <18%
were found to be independent predictors of adverse effects.
INTERPRETATION Before using submandibular BoNT-A injections for drooling, potential
adverse effects should be discussed. Oral motor function needs to be monitored, because
existing dysphagia may be worsened. The identified clinical predictors could be helpful to
optimize patient selection.
Treatment with botulinum neurotoxin (BoNT) in the sali-
vary glands is a widely accepted effective intervention for
drooling in children with central nervous system (CNS)
disorders. When injected into the salivary glands, BoNT
inhibits the acetylcholine release at the terminal nerve end-
ings, decreasing the secretion of saliva and diminishes
drooling in the majority of patients.1
The main group of children with neurological impair-
ments treated with BoNT injections are children with
cerebral palsy (CP), a vulnerable group with a spectrum of
oral motor problems (estimated 40% drooling preva-
lence).2–4 Drooling has a serious impact on the children’s
social interaction, self-esteem, and health.5 The effective-
ness of salivary gland BoNT has been studied extensively,
although the debate about which glands should be injected
is still going on. Several studies demonstrated that, after
BoNT, drooling is significantly reduced. In Scheffer’s
study a clinically notable response was found in 46.6% of
children.6 The duration of this effect was approximately 2
to 6 months (median 24wks).6–8 In most of these studies,
botulinum neurotoxin A (BoNT-A) was used.9
Considering the increasing use of BoNT for drooling,
studies to identify possible risk factors for adverse effects
on oral motor functions before treatment are urgently
needed.10 Post-intervention assessments showed that
adverse effects on oral motor functions with a potential
negative effect on swallowing occurred from 0%11–13 up
to 17.8%6 of the cases after submandibular gland injec-
tions, and up to 33%14 of the cases after combined sub-
mandibular/parotid gland injections. To date no major
complications were identified after submandibular
injections.
Knowledge of the incidence, nature, and risk factors of
adverse effects will help to predict which children with
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CNS disorders will positively qualify for BoNT to amelio-
rate excessive drooling.
The objectives of this study were: (1) to determine what
adverse effects on oral motor function occur up to 8
months after the first BoNT-A injections in the sub-
mandibular glands; (2) to describe the incidence and course
of these adverse effects; and (3) to identify independent
predictors for adverse effects on oral motor function.
METHOD
Design and patient selection
In this cohort study, 209 children (123 males, 86 females;
median age at inclusion 8y 4mo, aged 4–27y) participated.
Inclusion criteria were: (1) first treatment with BoNT-A
injections in the submandibular glands in the period
between January 2002 and May 2013; (2) moderate to sev-
ere drooling with a score of three or higher on the Tea-
cher Drooling Scale (occasional drooling, intermittent, all
day); (3) minimum age of 4 years; (4) a minimum of two
measurements representing baseline and at least one follow
up; and (5) no previous surgical procedure for saliva con-
trol. Informed consent for BoNT-A treatment was
obtained from the child’s legal representative(s). Parents or
caregivers were informed about the consequences and the
expectations of the treatment before the injections. All
injections were administered as part of regular care.
Patient characteristics
All children were assessed before treatment by members of
the multidisciplinary saliva control team of the Radboud
University Medical Centre. A medical assessment was per-
formed by the pediatric neurologist and the ear, nose, and
throat (ENT) specialist. Two specifically trained speech
and language therapists (SLTs) carried out a social evalua-
tion and an oromotor assessment. The quantity of drooling
and the impact of the intervention on the severity of drool-
ing were measured with objective and subjective scales at
three different moments: before (t1), 8 weeks (t2), and 32
weeks after the injections (t3). The severity of drooling
was quantified with the modified drooling quotient.15 A
caretaker visual analogue scale score (range 0–10) reflected
the severity of drooling, with 0 indicating ‘no drooling’
and 10 indicating very severe drooling.5 Based on direct
SLT observations and parental reports, the viscosity of sal-
iva was judged before and after BoNT-A (more serous/
more mucus/unchanged).
Treatment characteristics
Intraglandular injections of BoNT-A (Botox; Allergan,
Nieuwegein, the Netherlands) were performed by the
team’s pediatric rehabilitation specialist under ultrasound
guidance and general anesthesia. Treatment consisted of
bilateral injections in the submandibular glands. Botox was
diluted in saline 0.9% (25U/mL). Using a Spinocan needle,
1ml was divided over two or three sites throughout the
gland. Occasionally, slightly more BoNT-A was injected to
attain optimal spread, up to a maximum of 30U Botox per
gland. For every child the applied dosage of BoNT-A per
gland was noted in the medical records. The clinically rele-
vant response at t2 to BoNT-A treatment was defined as
≥50% reduction in drooling quotient and/or a reduction of
2 standard deviations from the baseline visual analogue
score to obtain a combined objective and subjective
outcome.6
Adverse effects
If the caregivers noticed any post-treatment change in oral
motor function during the first 8 weeks, they were encour-
aged to contact the SLT for advice and, if needed, they
were invited for an additional visit at the outpatient clinic.
Adverse effects were elicited as a part of our usual care
during each follow up moment at 8 weeks and 32 weeks
through a semi-structured interview. During the SLT mea-
surements at t2 and t3, we specifically asked for any proba-
ble adverse effect or change in health condition. Negative
oral motor problems were recorded and categorized
according to the International Classification of Function-
ing, Disability and Heath, Children and Youth version
(ICF-CY). Five subdomains remained: (1) saliva swallow-
ing=reported changes in saliva viscosity, increased choking
on saliva, and/or reported discomfort during swallowing
saliva; (2) eating=reported discomfort during eating
(coughing, gagging), deteriorated feeding pattern; (3)
drinking=reported discomfort during drinking (coughing,
choking, dyspnoea); (4) articulation=reported deteriorated
speech; (5) other problem=reported other discomfort, as
sore throat, dry mouth/lips, and teeth grinding. Adverse
effects were subdivided into three categories: mild, moder-
ate, and severe (definitions in Table II). The predefined
outcome definition was dichotomous: adverse effects occur-
rence ‘yes’ versus ‘no’.
Statistics
Descriptive statistics were used to determine general char-
acteristics of the children and allocated treatments, and the
incidence and occurrence of the adverse effects. Medians
and minimal/maximal values were calculated for continu-
ous variables. The association between post BoNT-A saliva
viscosity (more concentrated mucus saliva) and the appear-
ance of adverse effects was calculated by a chi-squared test,
as well as the relationship between the occurrence of
adverse effects and the response to BoNT-A injections.
Univariable logistic regression was used to study associa-
tions between patient characteristics, the BoNT-A dosage,
and the occurrence of adverse effects. The adverse effects
prevalence (n) and the crude odds ratio (OR) with 95%
What this paper adds
• Transient adverse effects of submandibular botulinum neurotoxin A (BoNT-A)
injections on oral motor function occur in 33% of all cases.
• Predictors of the occurrence of adverse effects of BoNT-A treatment are
diagnosis of cerebral palsy, higher dosage of BoNT-A, and a pre-treatment
drooling quotient <18%.
• Although BoNT is a valuable treatment for drooling, careful evaluation
before treatment and aftercare are crucial.
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confidence intervals (CI) are presented. Potential predictors
of adverse effects incorporated in the model were based on
biological plausibility and a previous publication of the
drooling quotient.15 Model selection was done using back-
ward stepwise elimination with p=0.100 levels of removal.
Results with two-tailed p-values <0.050 were considered
significant. The adjusted ORs with 95% CI of the final
model were calculated. The area under the curve (AUC) of
the receiver operating characteristic (ROC) curve was used
as a measure of predictive discrimination. Missing descriptive
values were considered as missing completely at random
(MCAR). To calculate treatment responses, missing values of
drooling quotient and visual analogue scores were imputed
according to the worst-case scenario: missing data were
replaced with the last previous observation or replaced by
baseline values. Statistical analyses were carried out using
SPSS 20.0 for Windows (IBM Corp., Armonk, NY, USA).
RESULTS
Patient and treatment characteristics
Our data set of 209 children contained 130 children with
CP (62.2%), whereas 78 children (37.3%) were classified as
non-CP (e.g. epileptic encephalopathy or neurogenetic
syndromes) (Table I). The disease course was complicated
by intractable seizures in 18 children (8.6%). All children
had received bilateral submandibular BoNT-A injections,
182 (87.1%) with a dosage of 25U, 16 (7.7%) had received
<25U per gland, and 8 (3.8%) had received more than
25U per gland. Most children (n=136; 65%) were classified
as responders, whereas 73 (35%) were considered to be
non-responders at t2.
Adverse effects
The incidence and characteristics of the adverse effects are
listed in Table II together with the advices and interven-
tions given post treatment. Adverse effects were recorded
in 69 (33%) of the children. Of the 69 children with
adverse effects, 22 children (31.9%) experienced saliva
swallowing, 51 (73.9%) eating, 22 (31.9%) drinking, 4
(5.8%) articulation, and 15 (21.7%) other problems. In 37
children (53.6%) with any type of adverse effects, an iso-
lated oral motor problem occurred. Simultaneous problems
co-occurred in two domains in 23 (33.3%), in three
domains in 5 (7.2%), and in four domains in four children
(5.8%). Severe adverse effects appeared to be related to the
occurrence of multiple problems in one individual at the
same time. Of the six children with severe adverse effects,
only one child reported one problem, whereas one child
experienced two problems, two children three problems,
and two children four problems at the same time. In 54
(78.3%) the onset of the adverse effects occurred within 1
week after treatment, while complete disappearance
occurred in 37 children (53.6%) before the end of the
fourth week post treatment. Two children experienced
adverse effects longer than 8 months. The severity of the
adverse effects was mild in 55 (79.7%) and no post-treat-
ment intervention was needed in 50 of these children
Table I: Characteristics of study population at baseline (t1) (n=209)
Patient characteristics n (%)
Sex
Male 123 (58.9)
Female 86 (41.1)
Age at inclusion
Median 8.4 (4.1–27.8)a
Diagnosis
CP 130 (62.2)
Non-CPb 78 (37.3)
Unknown 1 (0.5)
Disease coursec
Complicated 18 (8.6)
Non-complicated 190 (90.9)
Unknown 1 (0.5)
Mental ability
Developmental age <4y 131 (62.7)
Developmental age >4y 78 (37.3)
Degree of mobility
Ambulant 104 (49.8)
Non-ambulant 105 (50.2)
Cause of drooling
Low cognitive awareness 25 (12)
Impaired oral phase of swallowing 126 (60.2)
Impaired oropharyngeal phase of swallowing 58 (27.8)
Nutrition intake
Tube/tube and oral 34 (16.3)
Oral 175 (83.7)
Choking on saliva
Yes 59 (28.2)
No 145 (69.4)
Unknown 5 (2.4)
Choking on food
Yes 96 (45.9)
No 109 (46.8)
Unknown 4 (1.9)
Choking on drinks
Yes 107 (51.2)
No 99 (47.4)
Unknown 3 (1.4)
DQ
Median 27.5 (0–100)a
Unknown 2 (1)
VAS
Median 8 (3.4–10)
Unknown 2 (1)
Treatment characteristics:
Dosage of BoNT-A per gland, n (%)
Dosage<25U 16 (7.7)
Dosage=25U 182 (87.1)
Dosage>25U 8 (3.8)
Unknown 3 (1.4)
Saliva viscosity at t2, n (%)
More serous 17 (8.1)
More mucus 76 (36.4)
Unchanged 76 (36.4)
Unknown 40 (19.1)
Treatment response,d n (%)
Responder 136 (65.1)
Non-responder 73 (34.9)
aData of age, DQ and VAS are presented as median (min/max).
bNon CP: children with developmental disability mainly as part of a
syndrome, genetic, metabolic or neurodegenerative disorder.
cComplicated: in case of a progressive disease or if something
unexpected happened (e.g. uncontrolled epilepsy), Non-compli-
cated: when the course did not deviate from expected. dTreatment
response: treatment with BoNT-A was defined as effective and clin-
ically useful if ≥50% reduction in DQ was found and/or if a reduc-
tion of ≥3.86 (2SD) of the VAS score (0–10) occurred at t2
compared to t1. CP, cerebral palsy; y, year; BoNT-A, Botulinum
neurotoxin A; t1, baseline; U, unit; DQ, drooling quotient; VAS,
visual analogue scale.
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(72.5%). Of the children who experienced severe adverse
effects, 4 (5.8%) needed hospital admission or required a
substantial change in feeding or a nasogastric tube feed for
a few weeks (2.9%). Concerning the phone calls by SLTs
and additional outpatient visits, advice involved medication,
the adaptation of the food consistency, supportive care,
and explanation of the problem (21.7% of the cases).
In 76 of the 209 cases (36.4%) saliva became more mucus
at t2. Increased viscosity of saliva was positively related to
the occurrence of an adverse effect (X2 [1, n=209]=11.5,
p=0.001). No relation was found between the occurrence of
adverse effects and being a responder or non-responder to
BoNT-A injections at t2 (X2 [1, n=209]=0.42, p=0.521).
Prediction model
In Table III, crude ORs and adjusted ORs are given for the
biologically plausible risk factors for any adverse effect. The
ordinal category with the suspected lowest adverse effect
chance was chosen as a reference. Statistically significant
predictors of adverse effects were having a diagnosis of CP,
higher dosage of BoNT-A, and a pre-treatment drooling
quotient below 18%. When all other variables remained
stable, children with CP were 3 times more likely to experi-
ence an adverse effect (OR: 3.08; 95% CI: 1.53–6.19) than
other children. Compared to children injected with <25U
Botox, treatment with a dosage of 25U Botox increased the
odds of experiencing an adverse effect by a factor 5 (OR:
5.06; 95% CI: 1.07–23.84), whereas children injected with
more than 25U Botox were eight times more likely to have
an adverse effect (OR: 8.13; 95% CI: 1.02–64.96). Lastly, a
pre-treatment drooling quotient <18% increased the odds
(OR: 2.40; 95% CI: 1.18–4.88) of developing adverse effects
compared with a pre-treatment drooling quotient ≥18%.
The AUC of the ROC curve for the multivariable regres-
sion analysis was 67% (95% CI: 60–75%).
DISCUSSION
To our knowledge this series represents the largest cohort
of children (n=209) who received BoNT-A injections
exclusively in the submandibular glands. Moreover, our
registration of adverse effects was based on a standardized
face-to-face contact 8 weeks and 32 weeks post injections.
From this study it can be concluded that adverse effects on
oral motor functions occur in 33% of the children but, at
the same time, that almost 80% of the adverse effects were
‘mild’ and 54% disappeared within 4 weeks after the injec-
tions. By categorizing the oral motor problems after
BoNT-A in different domains, we found that eating prob-
lems were reported the most, followed by (saliva) swallow-
ing and drinking problems. Only the group of children with
moderate and severe adverse effects (n=13) needed advice
and supervision of the SLT or physician. Considering the
pharmacology of BoNT-A, two individuals exhibited unex-
plained adverse effects lasting longer than 32 weeks, as the
normal (median) duration of BoNT efficacy for drooling is
22 weeks.6
In previous studies, the incidence of mild or moderate
complications of submandibular BoNT injections in chil-
dren ranged from 0% to 17.8%.6,11–13 In the present study
we found such complications in 29.7% of the cases, whereas
severe adverse effects occurred in 2.9%. Because protocols
differed between studies with respect to intervention and
follow-up, we estimated the percentages of patients with
complications per treatment. Most studies reported compli-
cations after combined BoNT injections into the parotid
and submandibular glands, or after repeated salivary gland
Table II: Incidence and characteristics of adverse effects of first
botulinum neurotoxin A (BoNT-A) injections in the submandibular glands
as well as advices/interventions given post treatment (n=209)
n (%)
A. Incidence of adverse effects
Adverse effects
Yes 69 (33.0)
No 140 (67.0)
B. Characteristics of adverse effects (n=69)
Severity of problema
Mild 55 (79.7)
Moderate 7 (10.1)
Severe 6 (8.7)
Not specified 1 (1.5)
Oral motor problemb
Saliva swallowing problems 22 (31.9)
Eating problems 51 (73.9)
Drinking problems 22 (31.9)
Articulation problems 4 (5.8)
Other 15 (21.7)
Number of co-occurring oral motor problems
1 37 (53.6)
2 23 (11.0)
3 5 (2.4)
4 4 (1.9)
Time of problem onset
<1wk 54 (78.3)
1–8wks 5 (7.2)
Unknown 10 (14.5)
Duration of problem
<1wk 12 (17.4)
1–4wks 25 (36.2)
4–8wks 6 (8.7)
8–32wks 7 (10.2)
>32wks 2 (2.9)
Unknown 17 (24.6)
C. Post treatment advices/interventions
Interventions
None 50 (72.5)
Phone consultancy 11 (15.9)
Additional outpatient visit 3 (4.3)
Hospital admission 4 (5.8)
Otherc 1 (1.5)
Advices
Start (or increase) of tube feeding 2 (2.9)
Adapt feeding/consistency 9 (13.0)
Medication 1 (1.5)
Other 5 (7.2)
None 50 (72.5)
Unknown 2 (2.9)
aMild: short transient changes in saliva swallowing, eating, drink-
ing, or articulation, not leading to changes in lifestyle or doctor vis-
its. Moderate: transient changes in oral motor functions or losing
weight, nearly always requiring consultation by a general practi-
tioner. Severe: change in oral motor function requiring one or more
days of hospitalization or substantial changes in feeding (e.g. tube
feeding). bMultiple problems per child are possible. cOther: combi-
nation of advice or interventions.
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injections in the same individual.14,16–18 Chan et al.19 found
15.8% complications after combined injections with major
complications in 4% of the cases. In a study by Khan et al.,
15 of the 45 patients (33.3%) experienced at least one prob-
lem after combined injections. Major problems requiring
intensive therapy and prolonged hospitalization occurred in
11.1% of the cases.14 The adverse effect definition and
strict follow-up protocol in our study may be the reason for
the relatively high adverse effect percentages. However, it
should be noted that some adverse effects in Chan et al.’s19
study may not have been recognized because of possible
recall bias (telephone survey response rate 51%). In conclu-
sion we see fewer severe adverse effects (2.9%) after the
two-gland method with isolated submandibular injections
than after the four-gland method with combined parotid
and submandibular gland injections (4–11.1% complica-
tions); this, as also indicated by Gok et al.,13 would be the
first choice in saliva control treatment when BoNT-A injec-
tions are considered in children.
Children with CNS disorders who are treated for drool-
ing are vulnerable with regard to their oral motor abilities.
In present study, 28.2 to 51.2% already showed dysphagia
at baseline. After BoNT-A, the oral motor problems
increased in 69 children (33%). As expected, a higher fre-
quency of adverse effects occurred in children with oral
feeding skills (87%). Our findings underline the recom-
mendation by Reddihough et al.1 to regularly contact the
patient’s caregivers in the weeks after BoNT injections to
evaluate oral motor problems.
Authors mentioned two main causes for the deteriora-
tion of swallowing and/or speech. Higher salivary viscosity
after BoNT-A injections may result in problems with
intraoral processing of (solid) food.20,21 Indeed, we found a
significant association between increased salivary viscosity
and the occurrence of adverse effects. Concerning oral
motor function, the second potential cause of BoNT-
related problems is the diffusion of the toxin outside the
salivary gland leading to muscle weakness.6,20 The
Table III: Number of patients with and without adverse effects (AE+/) and ORs and adjusted ORs with 95% confidence interval based on univariable
and multivariable logistic regression analysis with AUCa respectively
Number of patients
Characteristics AE (%) (n=140) AE+ (%) (n=69) OR (95% CI) Adjusted OR (95% CI)
Sex
Male 81 (57.9) 42 (60.9) 1.00 (reference) –
Female 59 (42.1) 27 (39.1) 0.88 (0.49–1.59) –
Developmental age
<4y 91 (65.0) 40 (58.0) 1.35 (0.75–2.43) –
≥4y 49 (35.0) 29 (42.0) 1.00 (reference) –
Diagnosis
Non CP 61 (43.9) 17 (24.6) 1.00 (reference) 1.00 (reference)
CP 78 (56.1) 52 (75.4) 2.39 (1.26–4.54) 3.08 (1.53–6.19)b
Unknown 1
Degree of mobility
Ambulant 75 (53.6) 29 (42.0) 1.00 (reference) –
Non-ambulant 65 (46.4) 40 (58.0) 1.59 (0.89–2.85) –
Injected dosage BoNT per gland
<25U 14 (10.2) 2 (2.9) 1.00 (reference) 1.00 (reference)
25U 119 (86.9) 63 (91.3) 3.71 (0.82–16.82) 5.06 (1.07–23.84)b
>25U 4 (2.9) 4 (5.8) 7.00 (0.92–53.23) 8.13 (1.02–64.96)b
Unknown 3
Nutrition intake
Tube/tube and oral 25 (17.9) 9 (13.0) 1.00 (reference) –
Oral 115 (82.1) 60 (87.0) 1.45 (0.64–3.30) –
Choking on saliva (t1)
No 98 (70.5) 47 (72.3) 1.00 (reference) –
Yes 41 (29.5) 18 (27.7) 0.92 (0.48–1.76) –
Unknown 1 4
Choking on food (t1)
No 77 (55.8) 32 (47.8) 1.00 (reference) –
Yes 61 (44.2) 35 (52.2) 1.38 (0.77–2.48) –
Unknown 2 2
Choking on drinks (t1)
No 67 (48.6) 32 (47.1) 1.00 (reference) –
Yes 71 (51.4) 36 (52.9) 1.06 (0.59–1.90) –
Unknown 2 1
DQ (t1)
DQ<18 87 52 1.94 (1.01–3.75) 2.40 (1.18–4.88)b
DQ≥18 52 16 1.00 (reference) 1.00 (reference)
Unknown 1 1
aThe area under the ROC curve for multivariable logistic regression analysis was 67% (95% CI: 60–75%). bSignificant predictors of adverse
effects based on multivariable logistic regression analysis. AE+, patients with adverse effects; AE, patients without adverse effects; OR,
odds ratio; –, variables not selected in the multivariable logistic regression analysis.
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submental muscle group (SMG) plays an important part in
normal swallowing.22,23 After submandibular BoNT, diffu-
sion into the SMG most likely results in muscle weakness
and, as a consequence, the child may not properly control
the swallowing process leading to oral dysfunction.
Up to now, it has been unknown which children with
CNS disorders will experience adverse effects after BoNT
treatment. We tried to discover potential risk factors and
identified three clinically significant predictors of the occur-
rence of adverse effects: diagnosis of CP, higher BoNT-A
dosage, and pre-treatment drooling quotient of <18%.
Children with CP were three times more likely to expe-
rience an adverse effect than other children. This finding
may be attributed to the fact that, in children with CP,
drooling is generally caused by an impaired oropharyngeal
swallowing caused by poor oral muscle control.3,16 In other
children with CNS disorders drooling is usually less associ-
ated with motor control, but more commonly caused by
less awareness and inability to recognize salivary spill.17
We hypothesize that, in some children with CP, changes
in the viscoelastic properties and the decreased salivary
amount, or induced muscle weakness, cannot adequately be
compensated by the oral motor system.
In the present study we had the opportunity to compare
different dosages of BoNT per submandibular gland. Chil-
dren treated with 25U and >25U Botox per gland were
more at risk of an adverse effect (5 and 8 times higher risk
respectively). Recently, Moller et al.9 found no relationship
between adverse effects and the administered dose or injec-
tion method of BoNT-A. Some authors have speculated
whether a high volume of liquid or a slower speed of deliv-
ery may affect the likelihood of dispersal into surrounding
tissues.18 Currently, the most effective dilution of BoNT
and the number of injection sites within the gland are still
under debate. Normally, the amount of fluid injected raises
the intraglandular pressure and, theoretically, leakage of
the drug might occur. Tighe et al.24 also recently reported
dysphagia after BoNT-A extravasation from the glandular
puncture site, possibly depending on the injected volume.
At baseline, children who had a drooling quotient <18
(i.e. mild drooling) were 2.4 times more likely to develop
an adverse effect. The drooling quotient is a reliable objec-
tive measure of unintentional loss of saliva from the
mouth. In a previous study by our team, we concluded that
children with a drooling quotient <18 may be eligible for a
more conservative intervention, such as oral sensorimotor
training. In cases when those children receive BoNT,
because of a failure of the oral motor training and the high
impact of the drooling, the mouth could possibly become
dry, interfering with mastication. On the other hand, the
drooling quotient is a measurement for anterior (visible)
drooling and children with a low drooling quotient might
be sensitive to posterior drooling, making them more vul-
nerable to adverse effects – i.e. those children lack the
strength to process the thickened saliva making them prone
to saliva swallowing problems. We argue that this cut-off
threshold should not be applied as the only variable to
indicate an invasive treatment. The use of subjective mea-
surements of the severity and impact of drooling on the
child and parents should also be encouraged.15
Interestingly, we could not find a relation between the
occurrence of an adverse effect and being a responder or
not. Thus, we are convinced that it is justified to treat chil-
dren with CNS disorders for chronic drooling because the
majority of the adverse effects are mild and will improve
within a few weeks in most of the cases.
A limitation of our study is that we focused on a limited
set of factors that might influence the occurrence of
adverse effects. There may be other risk factors of impor-
tance such as the use and/or change of oral medication
during/after BoNT treatment. In addition, we did not doc-
ument any concurrent BoNT injections into the skeletal
muscles to treat spasticity. Indeed, disturbances of swallow-
ing and speech have been reported after multilevel intra-
muscular injections,25,26 because the total amount of
BoNT in the body is substantially increased after com-
bined intraglandular and intramuscular injections. Thus,
clinicians should be aware of the increased risk of oral
motor dysfunction if they treat both.
In conclusion, BoNT-A injections can reduce saliva pro-
duction and constitute one of the treatment options for
children with CNS disorders and excessive drooling. How-
ever, in one-third of the treatments, mild and transient oral
motor problems can be expected. A diagnosis of CP,
higher BoNT-A dosage, and mild visible drooling at base-
line are associated with an increased risk of oral motor
problems. However, more scientific research at both the
neurophysiological level (i.e. determinants of the entire
pharyngeal swallowing process) and the pharmaceutical
level (dose and concentration-finding) is needed. Moreover,
such treatment and subsequent follow-up should preferably
take place under the responsibility of a multidisciplinary
saliva control team that is capable of anticipation and
immediate management of adverse effects.
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